Halozyme Therapeutics (HALO) Tops Q4 EPS by 3c; Guides FY15 Revs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall St set to open higher after inflation data, earnings boost
- Oil prices rise after ship attacks, US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Halozyme Therapeutics (HALO) PT Raised to $26 at BMO Capital
March 3, 2015 7:23 AM ESTBMO Capital analyst Jim Birchenough reiterated an Outperform rating and boosted his price target on Halozyme Therapeutics (NASDAQ: HALO) to $26.00 (from $24.00) following Q4 results.
Birchenough commented, "We are reiterating our Outperform rating on the shares of HALO following review of 4Q14 progress.... More
Halozyme Therapeutics (HALO) Raised to $19 at Piper Jaffray
March 3, 2015 7:17 AM ESTPiper Jaffray analyst Charles Duncan reiterated an Overweight rating and boosted his price target on Halozyme Therapeutics (NASDAQ: HALO) to $19.00 (from $17.00) following Q4 results.. The firm said proprietary program visibility should increase in 2015.
Duncan commented, "On Monday AMC, Halozyme reported 4Q/FY14 results, reiterating 2015... More
